Search

Your search keyword '"Toshitaka, Nakamura"' showing total 476 results

Search Constraints

Start Over You searched for: Author "Toshitaka, Nakamura" Remove constraint Author: "Toshitaka, Nakamura"
476 results on '"Toshitaka, Nakamura"'

Search Results

1. Inhibition of 7-dehydrocholesterol reductase prevents hepatic ferroptosis under an active state of sterol synthesis

2. Efficacy of the MRA-Based Road Mapping of the Para-Aortic Access Route before Mechanical Thrombectomy in Patients with Acute Ischemic Stroke

3. National trends in the outcomes of subarachnoid haemorrhage and the prognostic influence of stroke centre capability in Japan: retrospective cohort study

4. Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)

5. Trends in Hip Fracture Incidence in Japan: Estimates Based on Nationwide Hip Fracture Surveys From 1992 to 2017

6. Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis

7. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial

9. Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study

11. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study

12. Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study

13. Circulating tumor cells detected only after surgery for non-small cell lung cancer: is it a predictor of recurrence?

14. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis

15. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status

16. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05

17. A non-canonical vitamin K cycle is a potent ferroptosis suppressor

18. Author response for 'The Interaction of Acute‐Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial'

19. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial

20. Endoscopic Shelf Acetabuloplasty Combined With Labral Repair, Cam Osteochondroplasty, and Capsular Plication for Treating Developmental Hip Dysplasia

21. The mitochondrial Ca 2+ uptake regulator, MICU1, is involved in cold stress‐induced ferroptosis

22. The mitochondrial Ca

23. Incidence of hip and subtrochanteric/femoral shaft fractures in postmenopausal women with osteoporosis in the phase 3 long-term odanacatib fracture trial

24. Postoperative Adjuvant Anastrozole for 10 Rather than 5 Years in Patients with Oestrogen Receptor-Positive Breast Cancer: AERAS, a Randomised Multicentre Open-Label Phase III Trial

26. Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy

27. A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis

29. An Allopurinol-Controlled, Multicenter, Randomized, Open-Label, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan: Phase 2 Exploratory Clinical Study

31. The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis

32. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study

33. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04

34. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

35. Improved periodontal disease and prevention of tooth loss in osteoporosis patients receiving once-yearly zoledronic acid: a randomized clinical trial

36. Complication rate, cure rate, and long-term outcomes of microsurgery for intracranial dural arteriovenous fistulae: a multicenter series and systematic review

37. A Pilot Study on Measuring Tissue Motion During Carotid Surgery Using Video-Based Analyses for the Objective Assessment of Surgical Performance

38. Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases

39. Clinical Results of the New Cervico-Thoracic Orthosis ‘Neck-Chest Brace’

40. Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis

41. Treatment responses with once-weekly teriparatide therapy for osteoporosis

42. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice

43. Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03

44. Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study

45. Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04

47. Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study

48. Decreased rate of hip fracture and consequent reduction in estimated medical costs in Japan

49. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis

50. Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan

Catalog

Books, media, physical & digital resources